COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Police COVID-19 Serosurvey (PoliCOV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04643444
Recruitment Status : Recruiting
First Posted : November 25, 2020
Last Update Posted : December 28, 2020
Sponsor:
Collaborator:
Interregionale Blutspende SRK Bern
Information provided by (Responsible Party):
University of Bern

Brief Summary:
The investigators aim to determine the immune status of the employees of the cantonal police of Bern against SARS-CoV-2 over a period of 1 year, and to investigate the risk profile of the study participants and their risk of SARS-CoV-2 exposure in their working and private environments, as well as to evaluate the use of personal protective equipment at potential exposure instances.

Condition or disease Intervention/treatment
SARS-CoV-2 Infection Volunteers Healthy Diagnostic Test: Blood sampling Other: Online Questionnaire

Detailed Description:

i) To determine the extent of infection with seroprevalence data in the special population of police officers of the canton Bern.

ii) To determine risk factors for infection by comparing the proportion of seropositivity (infected versus noninfected individuals). The investigators hypothesize that police officers with fieldwork activity will have a higher seroprevalence than will office and administration personnel. The investigators hypothesize that working in the city of Bern will be associated with a higher seroprevalence than will working in other geographic areas of the canton (i.e. rural area).

iii) To monitor COVID-19 antibody titres and neutralizing capacity over time and to associate them with reinfection rates and infection-free intervals in police officers after accidental contact with a proven COVID-19 case. The investigators hypothesize that in seropositive individuals, there will be a decreasing dynamic of antibody titres over the one-year study period, and hence, a decrease of neutralizing capacity.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Police Officer COVID-19 Seroprevalence Survey in the Canton of Bern, Switzerland
Estimated Study Start Date : January 2021
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : June 2022

Intervention Details:
  • Diagnostic Test: Blood sampling
    Testing for the presence of SARS-CoV-2 antibodies
  • Other: Online Questionnaire
    Questions on working place, risk profiles and PPE


Primary Outcome Measures :
  1. Seroprevalence [ Time Frame: One year ]
    The variable of primary interest is COVID-19 seropositivity. This variable is measured at five time points over the one-year study period. The following baseline factors may have an influence on the primary endpoint and will be obtained: (i) pre-existing comorbidities, (ii) rural versus city distribution of working place, and (iii) office work versus field work.


Secondary Outcome Measures :
  1. Risk profile assessment [ Time Frame: One year ]
    The investigators will assess the proportion of symptomatic and asymptomatic cases among seropositive participants. The investigators will calculate the attack rate in different subgroup. These include (i) study participants with health-related risk factors (age>50 and age>60 years, diabetes, arterial hypertension, cardiovascular disease, chronic pulmonary disease, immune-compromised status due to host diseases, medical treatment, cancer, obesity), (ii) activity-related subgroups (i.e. fieldwork vs office activity), (iii) geography-related subgroups (i.e. city vs rural areas). In follow-up visits, the antibody titers (i.e. dynamic) and the neutralization capacity will be assessed. Thereby, the investigators will determine the change in serum levels of SARS-CoV-2 antibodies over time in seropositive participants.


Biospecimen Retention:   Samples Without DNA
Serum


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Employees of the cantonal police of Bern, Switzerland
Criteria

Inclusion Criteria:

  • Police officers of the cantonal police of Bern volunteering to participate in the study.

Exclusion Criteria:

  • Refusal or inability to give informed consent or contraindication to venepuncture.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04643444


Contacts
Layout table for location contacts
Contact: Parham Sendi, MD +41316326986 parham.sendi@ifik.unibe.ch

Locations
Layout table for location information
Switzerland
University of Bern, Institute for Infectious Diseases Recruiting
Bern, BE, Switzerland, 3010
Contact: Parham Sendi, MD         
Sponsors and Collaborators
University of Bern
Interregionale Blutspende SRK Bern
Investigators
Layout table for investigator information
Principal Investigator: Parham Sendi, MD University of Bern
Layout table for additonal information
Responsible Party: University of Bern
ClinicalTrials.gov Identifier: NCT04643444    
Other Study ID Numbers: 2020-02650
First Posted: November 25, 2020    Key Record Dates
Last Update Posted: December 28, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University of Bern:
COVID-19
SARS-COV-2
Antibodies
Seroprevalence